No description available.

Klotho (KL), an anti-aging protein, attracted interest in the aging field because of the dramatic phenotype of KL deficient mice and its connection to signaling pathways implicated in aging. The KLVS variant consists of the F352V (KLV) and C370S (KLS) substitutions. It was detected in genome wide association studies (GWAS) that linked it to alterations in longevity and disease risk. The molecular mechanism(s) underlying these associations are unknown. To understand how KL increases the risk of age-related diseases, the studies in this dissertation investigated whether expression of the KLVS variant, when compared to wildtype (KLWT), displays differences in processing, protein-protein interactions and enzymatic activity. Differences in processing were evaluated by studying changes in shedding, half-life and plasma membrane localization of KL variants. The decrease in KLV shedding, as measured by the intracellular: extracellular ratio, were explained by a decreased half-life. This decreased half-life is potentially due to decreased KLV plasma membrane localization, which is attenuated by co-expression of dominant negative dynamin, suggesting a role of endocytosis in these differences. To assess whether there are changes in KLVS protein-protein interactions, differences in dimerization were measured by Blue Native gel electrophoresis and cross-linking. KLV dimerization was increased while KLS and KLVS variants decreased dimerization. Co-immunoprecipitation of tagged KL assessed whether these changes were due to alterations in homodimerization. The presence of KLVS in dimers decreased the levels of immunoprecipitated KL suggesting KLVS decreases homodimerization. Changes in heterodimerization of KLVS with fibroblast growth factor receptor (FGFR) 1c were also investigated through co-immunoprecipitation. KLVS increased heterodimerization with FGFR1c. Addition of FGF23, for which KL is a co-receptor, showed that KLVS increases FGF signaling downstream of FGFR1c. To determine differences in enzymatic activity of KLVS, 4-metylumbelliferyl-beta-D-glucuronide was used to measure alterations in glucuronidase activity. Results showed that KLVS had decreased enzymatic activity compared to KLWT. These findings are the first to show that KLVS leads to differences in function as demonstrated by decreased homodimerization and enzymatic activity and increased heterodimerization with FGFR1c. Given the association of KLVS with disease and longevity, these results suggest that these functions are integral in KL's anti-aging role in humans.

Thyroid hormones (THs) play a fundamental role in brain function during development and adulthood. THs are essential regulators of neurogenesis, cell maturation and migration as well myelination and synaptogenesis. Neuroglial cells, including astrocytes and microglia are targets of TH and implicated in TH regulation; however, the regulation is not properly understood at the cellular level. In this study, TH regulation was investigated in vitro using human brain cell lines of astrocytes (Svg-P12) and microglia (HMC3). The cells were exposed to TH receptor agonist (triiodothyronine; T3) and inhibitors (amiodarone/1-850), of different concentrations, followed by RNA extraction and quantitative PCR. The gene expression of known TH regulated genes was studied for a better understanding of TH signaling in astrocytes and microglia. All target genes were successfully measured in both cell types. Interestingly, the regulatory effects of TH in astrocytes and microglia exhibited differences. In astrocytes, T3 exposure resulted in an upregulation in gene expression of DDX54 (DEAD-Box Helicase 54) and KLF9 (Krüppel-like factor 9) but did not affect other genes. Also, THR inhibitor exposure resulted in n upregulation in gene expression of DDX54 (DEAD-Box Helicase 54) and KLF9 (Krüppel-like factor 9) but did not affect other genes. Also, THR inhibitor exposure resulted in downregulation in gene expression of KLF9, NES (Nestin), PTGDS (Prostaglandin D2 Synthase) and MAPT (Microtubule Associated Protein Tau). In contrast, none of the TH regulated genes demonstrated a statistical significance in T3-treated microglia compared to control cells. However, THR inhibitor exposure resulted in a downregulation in gene expression of KLF9 and DDX54 and an upregulation of NES, PTGDS and MAPT. The observed differences indicate that TH signaling and regulation is different in microglia and astrocytes. The The differential signaling suggests that T3 does not regulate all of its target genes directly; rather, the regulatory effects of T3 may be exerted through complex mechanisms with other key factors involved. It can be concluded that astrocytes and microglia play important roles as mediators of the effects of THs in CNS development and function. However, further analysis is needed to acknowledge other key factors and TH signaling mechanisms influencing the gene expression in neuroglia.

Indiana University-Purdue University Indianapolis (IUPUI) / Hydrocephalus is a neurological disorder characterised by the pathological accumulation of cerebrospinal fluid (CSF) within the brain ventricles. Surgical interventions, including shunt placement, remain the gold standard treatment option for this life-threatening condition, despite these often requiring further revision surgeries. Unfortunately, there is currently no effective, pharmaceutical therapeutic agent available for the treatment of hydrocephalus. CSF is primarily produced by the choroid plexus (CP), a specialized, branched structure found in the ventricles of the brain. The CP comprises a high resistance epithelial monolayer surrounding a fenestrated capillary network, forming the blood-CSF barrier (BCSFB). The choroid plexus epithelium (CPe) critically modulates CSF production by regulating ion and water transport from the blood into the intraventricular space. This process is thought to be controlled by a host of intracellular mediators, as well as transporter proteins present on either the apical or basolateral membrane of the CPe. Though many of these proteins have been identified in the native tissue, exactly how they interact and modulate signal cascades to mediate CSF secretion remains less clear. Transient potential receptor vanilloid 4 (TRPV4) is a non-selective cation channel that can be activated by a range of stimuli and is expressed in the CP. TRPV4 has been implicated in the regulation of CSF production through stimulating ion flux across the CPe. In a continuous CP cell line, activation of TRPV4, through the addition of a TRPV4 specific agonist GSK1016790A, stimulated a change in net transepithelial ion flux and increase in conductance. In order to develop a pharmaceutical therapeutic for the treatment of hydrocephalus, we must first understand the mechanism of CSF secretion in health and disease. Therefore, a representative in vitro model is critical to elucidate the signaling pathways orchestrating CSF production in the CP. This research aims to characterize an in vitro culture model that can be utilized to study both the BCSFB and CSF production, to investigate and identify additional transporters, ion channels and intracellular mediators involved in TRPV4-mediated signaling in the CPe, primarily through a technique called Ussing-style electrophysiology which considers electrogenic ion flux across a monolayer. These studies implicated several potential modulators, specifically phospholipase C (PLC), phosphoinositide 3-kinase (PI3K), protein kinase C (PKC), intermediate conductance K+ channel (IK), transmembrane member 16A (TMEM16A), cystic fibrosis transmembrane conductance regulator (CFTR) and protein kinase A (PKA), in TRPV4-mediated ion flux.

The mass popularization of telecommunication services in recent years have resulted in a heavily loaded signaling network. The Signaling System number 7 (SS7) is used in fixed and wireless networks and is needed for call control and services such as caller ID, roaming, and for sending SMS. The traditional SS7 networks are expensive to lease and to expand, hence a new suite of protocols have been designed to carry signaling messages over IP. This suite contains a transport protocol called Stream Control Transmission Protocol (SCTP) and various user adaptation layer protocols such as M2PA, M2UA, M3UA, and SUA. To transport the highly loss and delay sensitive signaling messages over IP, it is mandatory that the transport protocol meets the high performance requirements of SS7. Not before the IP-solution has been tested in detail, will it replace significant parts of the national telephone network. In this thesis, the failover duration in the case of link failure was tested using the feature of SCTP called multi-homing. The results suggest that carrying SS7 signaling traffic over IP is possible, since the failover duration does not exceed the required limit. / Under de senaste åren har telekommunikationstjänster blivit allt mer populära, vilket har lett till ett tungt belastat signaleringsnätverk. The Signaling System number 7 (SS7) används i fasta och trådlösa nätverk och behövs för att kontrollera telefonsamtal och för tjänster såsom caller ID, roaming och för att skicka SMS. De traditionella SS7- nätverken är dyra att hyra och att expandera, varför en ny grupp av protokoll har designats för att bära signaleringsmeddelanden över IP. De nya protokollen innehåller ett transportprotokoll som heter Stream Transmission Control Protocol (SCTP) och flera adaptionslagerprotokoll, bl.a. M2PA, M2UA, M3UA och SUA. För att transportera de förlust- och förseningskänsliga signaleringsmeddelandena över IP, måste transportprotokollet möta de höga krav som SS7 har. Inte förrän IP-lösningen har testats ingående, kommer den att ersätta betydelsefulla delar av det nationella telefonnätet. I detta examensarbete har failovertiden mätts då en nätverkslänk mellan två noder har utsatts för ett avbrott. Resultaten pekar på att det är möjligt att bära SS7-trafik över IP eftersom failovertidskraven inte överstigs.

No description available.

Background: Toll-like receptors (TLRs) have been implicated in myocardial ischemia/reperfusion (I/R) injury. The TLR9 ligand, CpG-ODN has been reported to improve cell survival. We examined effect of CpG-ODN on myocardial I/R injury. Methods: Male C57BL/6 mice were treated with either CpG-ODN, control-ODN, or inhibitory CpG-ODN (iCpG-ODN) 1. h prior to myocardial ischemia (60. min) followed by reperfusion. Untreated mice served as I/R control (n. =10/each group). Infarct size was determined by TTC straining. Cardiac function was examined by echocardiography before and after myocardial I/R up to 14. days. Results: CpG-ODN administration significantly decreased infarct size by 31.4% and improved cardiac function after myocardial I/R up to 14. days. Neither control-ODN nor iCpG-ODN altered I/R-induced myocardial infarction and cardiac dysfunction. CpG-ODN attenuated I/R-induced myocardial apoptosis and prevented I/R-induced decrease in Bcl2 and increase in Bax levels in the myocardium. CpG-ODN increased Akt and GSK-3β phosphorylation in the myocardium. In vitro data suggested that CpG-ODN treatment induced TLR9 tyrosine phosphorylation and promoted an association between TLR9 and the p85 subunit of PI3K. Importantly, PI3K/Akt inhibition and Akt kinase deficiency abolished CpG-ODN-induced cardioprotection. Conclusion: CpG-ODN, the TLR9 ligand, induces protection against myocardial I/R injury. The mechanisms involve activation of the PI3K/Akt signaling pathway.

Background: Toll-like receptors (TLRs) have been implicated in myocardial ischemia/reperfusion (I/R) injury. The TLR9 ligand, CpG-ODN has been reported to improve cell survival. We examined effect of CpG-ODN on myocardial I/R injury. Methods: Male C57BL/6 mice were treated with either CpG-ODN, control-ODN, or inhibitory CpG-ODN (iCpG-ODN) 1. h prior to myocardial ischemia (60. min) followed by reperfusion. Untreated mice served as I/R control (n. =10/each group). Infarct size was determined by TTC straining. Cardiac function was examined by echocardiography before and after myocardial I/R up to 14. days. Results: CpG-ODN administration significantly decreased infarct size by 31.4% and improved cardiac function after myocardial I/R up to 14. days. Neither control-ODN nor iCpG-ODN altered I/R-induced myocardial infarction and cardiac dysfunction. CpG-ODN attenuated I/R-induced myocardial apoptosis and prevented I/R-induced decrease in Bcl2 and increase in Bax levels in the myocardium. CpG-ODN increased Akt and GSK-3β phosphorylation in the myocardium. In vitro data suggested that CpG-ODN treatment induced TLR9 tyrosine phosphorylation and promoted an association between TLR9 and the p85 subunit of PI3K. Importantly, PI3K/Akt inhibition and Akt kinase deficiency abolished CpG-ODN-induced cardioprotection. Conclusion: CpG-ODN, the TLR9 ligand, induces protection against myocardial I/R injury. The mechanisms involve activation of the PI3K/Akt signaling pathway.

Objective: Activation of PI3K/Akt signaling protects the myocardium from ischemia/reperfusion injury. MicroRNAs have been demonstrated to play an important role in the regulation of gene expression at the post-transcriptional level. In this study, we examined whether miR-130a will attenuate cardiac dysfunction and remodeling after myocardial infarction (MI) via PI3K/Akt dependent mechanism. Approaches and results: To determine the role of miR-130a in the proliferation and migration of endothelial cells, HUVECs were transfected with miR-130a mimics before the cells were subjected to scratch-induced wound injury. Transfection of miR-130a mimics stimulated the migration of endothelial cells into the wound area and increased phospho-Akt levels. To examine the effect of miR-130a on cardiac dysfunction and remodeling after MI, Lentivirus expressing miR-130a (LmiR-130a) was delivered into mouse hearts seven days before the mice were subjected to MI. Cardiac function was assessed by echocardiography before and for up to 21 days after MI. Ejection fraction (EF%) and fractional shortening (FS%) in the LmiR-130a transfected MI hearts were significantly greater than in LmiR-control and untransfected control MI groups. LmiR-130a transfection increased capillary number and VEGF expression, and decreased collagen deposition in the infarcted myocardium. Importantly, LmiR-130a transfection significantly suppressed PTEN expression and increased the levels of phosphorylated Akt in the myocardium. However, treatment of LmiR-130a-transfected mice with LY294002, a PI3K inhibitor, completely abolished miR-130a-induced attenuation of cardiac dysfunction after MI. Conclusions: miR-130a plays a critical role in attenuation of cardiac dysfunction and remodeling after MI. The mechanisms involve activation of PI3K/Akt signaling via suppression of PTEN expression.

Cardiac fibroblasts play an important role in myocardial remodeling by proliferating, differentiating, and secreting extracellular matrix proteins. Estrogen has been reported to have a number of cardioprotective properties. However, it is unclear whether estrogen affects cardiac fibroblast differentiation. The purpose of the present study was to investigate the effect of estrogen on angiotensin II-induced cardiac fibroblast proliferation and differentiation. Cardiac fibroblasts were stimulated with angiotensin II (1 μM) in the presence or absence of 17β-estradiol (100 nM). Pretreatment of cardiac fibroblasts with 17β-estradiol significantly inhibited angiotensin II-induced cardiac fibroblast proliferation and differentiation (indicated by a reduction in alpha-smooth muscle actin (α-SMA) expression) by 25% and 20%. Pretreatment of 17β-estradiol significantly reduced angiotensin II-increased levels of phospho-p38 mitogen-activated protein kinase (MAPK) by 40% and nuclear factor-κB (NF-κB) binding activity in cardiac fibroblasts by 55%. Our data suggests estrogen could have an anti-fibrotic effect through limiting cardiac fibroblast proliferation and differentiation, which are the critical steps in the pathogenesis of cardiac fibrosis.